	US 11,744,832 B2
	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
James D. Rodgers, Jupiter, FL (US); and Stacey Shepard, Wilmington, DE (US)
Assigned to Incyte Corporation, Wilmington, DE (US); and Incyte Holdings Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US); and Incyte Holdings Corporation, Wilmington, DE (US)
Filed on Mar. 8, 2022, as Appl. No. 17/689,510.
Application 14/020,505 is a division of application No. 13/076,220, filed on Mar. 30, 2011, granted, now 8,530,485, issued on Sep. 10, 2013.
Application 17/689,510 is a continuation of application No. 16/821,624, filed on Mar. 17, 2020, granted, now 11,331,320.
Application 16/821,624 is a continuation of application No. 16/177,602, filed on Nov. 1, 2018, granted, now 10,639,310, issued on May 5, 2020.
Application 16/177,602 is a continuation of application No. 15/960,069, filed on Apr. 23, 2018, granted, now 10,398,699, issued on Sep. 3, 2019.
Application 15/960,069 is a continuation of application No. 15/356,957, filed on Nov. 21, 2016, granted, now 9,974,790, issued on May 22, 2018.
Application 15/356,957 is a continuation of application No. 15/233,652, filed on Aug. 10, 2016, granted, now 9,814,722, issued on Nov. 14, 2017.
Application 15/233,652 is a continuation of application No. 15/173,057, filed on Jun. 3, 2016, granted, now 9,662,335, issued on May 30, 2017.
Application 15/173,057 is a continuation of application No. 14/711,576, filed on May 13, 2015, abandoned.
Application 14/711,576 is a continuation of application No. 14/274,948, filed on May 12, 2014, granted, now 9,079,912, issued on Jul. 14, 2015.
Application 14/274,948 is a continuation of application No. 14/020,505, filed on Sep. 6, 2013, granted, now 9,206,187, issued on Dec. 8, 2015.
Application 13/076,220 is a continuation of application No. 12/549,170, filed on Aug. 27, 2009, granted, now 8,541,425, issued on Sep. 24, 2013.
Application 12/549,170 is a continuation of application No. 11/637,545, filed on Dec. 12, 2006, granted, now 7,598,257, issued on Oct. 6, 2009.
Claims priority of provisional application 60/859,404, filed on Nov. 16, 2006.
Claims priority of provisional application 60/856,872, filed on Nov. 3, 2006.
Claims priority of provisional application 60/850,625, filed on Oct. 10, 2006.
Claims priority of provisional application 60/810,231, filed on Jun. 2, 2006.
Claims priority of provisional application 60/749,905, filed on Dec. 13, 2005.
Prior Publication US 2022/0395506 A1, Dec. 15, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 45/06 (2006.01); C07B 59/00 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61P 37/00 (2006.01); A61P 35/04 (2006.01); A61P 17/04 (2006.01); A61P 29/00 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 417/04 (2006.01); A61K 31/573 (2006.01)

CPC A61K 31/519 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61P 17/04 (2018.01); A61P 29/00 (2018.01); A61P 35/04 (2018.01); A61P 37/00 (2018.01); C07B 59/002 (2013.01); C07D 417/04 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07B 2200/05 (2013.01)]

11 Claims

1. A method of treating graft versus host disease in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier; wherein the composition is suitable for oral administration and for providing sustained release of the compound or the salt.